viewC4X Discovery Holdings PLC

C4X Discovery boosts working capital with oversubscribed placing

Funds from the share issue should provide C4X with at least twelve months working capital, assuming it gets its usual tax credits

C4X Discovery Holdings PLC -

C4X Discovery Holdings PLC (LON:C4XD), the AIM-listed drug discovery company, has raised £1.6mln through an oversubscribed placing at 15p a throw.

C4X shares closed at 15.25p yesterday and the placing was the equivalent of 10% of its share in issue.

The net proceeds will be used to further strengthen the company’s balance sheet as its partnering and strategic collaborations progress and will boost working capital during the progression of its pipeline portfolio.

C4X said the new funds should provide it with at least twelve months working capital, assuming that a material tax credit will be received both this year and in the first half of next year, as has been the case in previous years.

Clive Dix, chief executive, added: " We would like to thank Polar Capital and our other new and existing investors for their active support of C4XD and continued belief in our vision.

It is encouraging to see investor understanding of the ongoing long-term contribution of the life sciences industry and the value of innovative, early-stage drug discovery amidst the uncertainties generated by the COVID-19 pandemic.

"These additional resources will support our continuing scientific progress and commercial discussions across our portfolio."

Quick facts: C4X Discovery Holdings PLC

Price: 20.8 GBX

Market: AIM
Market Cap: £24.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...


C4X Discovery CEO welcomes start of Indivior trial and outlines new...

C4X Discovery PLC's (LON:C4XD) Chief Executive Clive Dix speaks to Proactive London about the start of clinical trials of a treatment for opioid dependence. The phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year. Dix...

on 25/8/20

2 min read